No area of cancer supportive care better illustrates the advances in our understanding of cellular and molecular biology, genetic engineering and the development of more effective yet often more toxic cancer treatments than that of hematopoietic growth factors. Myelosuppressive agents, with their potential hematopoietic toxicities, remain the mainstay of systemic treatment for both metastatic and early stage cancer. Hematopoietic Growth Factors in Oncology reviews and integrates the major advances in our understanding of the underlying molecular biology and pharmacology of these agents along with the results of well designed and executed randomized controlled trials of the erythroid stimulating agents, the myeloid growth factors and the new thrombopoietic agents, each addressing a major threat associated with bone marrow suppression accompanying cancer treatment. "Hematopoietic growth factors have revolutionized the treatment of patients with a spectrum of cancers and benign bone marrow disorders. This text addresses the mechanism of action and clinical impact of these cytokines. Leading investigators in the field provide and update of current state of knowledge and future challenges." – Steven T. Rosen, M.D. Series Editor
Author(s): Gary H. Lyman, David C. Dale (auth.), Gary H. Lyman, David C. Dale (eds.)
Series: Cancer Treatment and Research 157
Edition: 1
Publisher: Springer US
Year: 2011
Language: English
Pages: 433
Tags: Oncology
Front Matter....Pages i-xv
Front Matter....Pages 1-1
Introduction to the Hematopoietic Growth Factors....Pages 3-10
Early-Acting Hematopoietic Growth Factors: Biology and Clinical Experience....Pages 11-31
Granulocyte Colony-Stimulating Factors....Pages 33-53
Erythropoiesis-Stimulating Agents....Pages 55-74
Thrombopoietin Factors....Pages 75-93
Front Matter....Pages 95-95
Cyclic and Chronic Neutropenia....Pages 97-108
The Myeloid Growth Factors....Pages 109-125
Meta-Analysis of Randomized Controlled Trials of Granulocyte Colony-Stimulating Factor Prophylaxis in Adult Cancer Patients Receiving Chemotherapy....Pages 127-143
Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapy....Pages 145-165
Granulocyte Colony-Stimulating Factors and Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome....Pages 167-178
Front Matter....Pages 179-179
Do Erythropoietic-Stimulating Agents Relieve Fatigue? A Review of Reviews....Pages 181-194
Randomized Controlled Trials of the Erythroid-Stimulating Agents in Cancer Patients....Pages 195-215
Ten Years of Meta-analyses on Erythropoiesis-Stimulating Agents in Cancer Patients....Pages 217-238
Clinical Practice Guidelines for the Use of Erythroid-Stimulating Agents: ASCO, EORTC, NCCN....Pages 239-248
Front Matter....Pages 249-249
Thrombocytopenia and Platelet Transfusions in Patients with Cancer....Pages 251-265
Romiplostim....Pages 267-288
Eltrombopag....Pages 289-303
Front Matter....Pages 305-305
The Hematopoietic Growth Factors in Acute Leukemia: US Perspective....Pages 307-337
The Hematopoietic Growth Factors in Acute Leukemia: A European Perspective....Pages 339-362
The Hematopoietic Growth Factors in the Myelodysplastic Syndromes....Pages 363-382
Front Matter....Pages 305-305
Hematopoietic Growth Factors in Older Cancer Patients....Pages 383-402
The Economics of the Hematopoietic Growth Factors....Pages 403-418
Back Matter....Pages 419-433
